ACAD
32.4
-0.23
-0.70%
AEMD
4.82
-0.69
-12.52%
APRI
0.542
+0.002
+0.370%
ARNA
1.77
-0.02
-1.12%
ATEC
0.238
+0.002
+0.9318%
CNAT
2.85
-0.01
-0.35%
CRXM
0.19
0.00
0.00%
CYTX
0.34
-0.01
-2.86%
DXCM
65.96
-2.45
-3.58%
GNMK
6.07
-0.39
-6.04%
HALO
10.84
-0.11
-1.00%
ILMN
135.75
-2.84
-2.05%
INNV
0.096
+0.001
+1.053%
INO
11.18
+0.25
+2.29%
ISCO
3.85
-0.05
-1.28%
ISIS
57.56
0.00
0.00%
LGND
123.12
-0.85
-0.69%
LPTN
0.242
-0.036
-12.9137%
MBVX
0.725
+0.025
+3.5429%
MEIP
1.4
-0.04
-2.78%
MNOV
6.98
-0.07
-0.99%
MRTX
21.04
-0.31
-1.45%
MSTX
0.301
-0.009
-2.9668%
NBIX
46.9
+0.66
+1.43%
NUVA
53.1
-1.32
-2.43%
ONCS
1.95
+0.07
+3.72%
ONVO
2.75
-0.04
-1.43%
OREX
0.467
+0.012
+2.5269%
OTIC
14.62
-0.93
-5.98%
QDEL
17.68
-1.59
-8.25%
RCPT
231.96
0.00
0.00%
RGLS
6.16
-0.06
-0.96%
RMD
56.5
-0.15
-0.26%
SCIE
0.003
0.00
+11.111%
SPHS
1.2
-0.05
-4.00%
SRNE
6.9
-0.02
-0.29%
TROV
4.16
-0.28
-6.31%
VICL
0.395
-0.008
-2.082%
VOLC
18
0.00
0.00%
ZGNX
10.63
-0.2
-1.85%
ACAD
32.4
-0.23
-0.70%
AEMD
4.82
-0.69
-12.52%
APRI
0.542
+0.002
+0.370%
ARNA
1.77
-0.02
-1.12%
ATEC
0.238
+0.002
+0.9318%
CNAT
2.85
-0.01
-0.35%
CRXM
0.19
0.00
0.00%
CYTX
0.34
-0.01
-2.86%
DXCM
65.96
-2.45
-3.58%
GNMK
6.07
-0.39
-6.04%
HALO
10.84
-0.11
-1.00%
ILMN
135.75
-2.84
-2.05%
INNV
0.096
+0.001
+1.053%
INO
11.18
+0.25
+2.29%
ISCO
3.85
-0.05
-1.28%
ISIS
57.56
0.00
0.00%
LGND
123.12
-0.85
-0.69%
LPTN
0.242
-0.036
-12.9137%
MBVX
0.725
+0.025
+3.5429%
MEIP
1.4
-0.04
-2.78%
MNOV
6.98
-0.07
-0.99%
MRTX
21.04
-0.31
-1.45%
MSTX
0.301
-0.009
-2.9668%
NBIX
46.9
+0.66
+1.43%
NUVA
53.1
-1.32
-2.43%
ONCS
1.95
+0.07
+3.72%
ONVO
2.75
-0.04
-1.43%
OREX
0.467
+0.012
+2.5269%
OTIC
14.62
-0.93
-5.98%
QDEL
17.68
-1.59
-8.25%
RCPT
231.96
0.00
0.00%
RGLS
6.16
-0.06
-0.96%
RMD
56.5
-0.15
-0.26%
SCIE
0.003
0.00
+11.111%
SPHS
1.2
-0.05
-4.00%
SRNE
6.9
-0.02
-0.29%
TROV
4.16
-0.28
-6.31%
VICL
0.395
-0.008
-2.082%
VOLC
18
0.00
0.00%
ZGNX
10.63
-0.2
-1.85%
Home » Archive by Category

Syndication

Web Marketing & SEO Sales: $30,000 + Commission / RECENT GRADS WANTED! (San Diego)

February 11, 2016 – 11:26 am

Expanding Company / Career Growth Opportunity
Expanding internet marketing company now interviewing an Internet Marketing Sales Representative. The products you will be selling are a customized suite of online marketing solutions for health and well […

Courier (Independent Contractor)

February 11, 2016 – 10:27 am

A Biotech Company is seeking to contract services of an Independent Contract Courier to pick up samples from the San Diego & La Jolla, CA areas & deliver to our La Jolla Laboratory. Samples will be picked up on an as needed basis; Monday – Friday, be […]

Changing the Future

February 11, 2016 – 7:00 am

UC San Diego Division of Social Sciences alumna Helen Griffith had little interest in a career in education when she came to campus as a transfer student. There was no way, she said, she would work around the clock…

Innovative Cell-Isolation System Points to New Model of Clinical Biopsy for Precise Characterization, Diagnosis and Treatment of Tumors

February 11, 2016 – 3:00 am

Scientific Study Shows DEPArray(TM) Digital Technology Enables Unambiguous Genetic Analysis of Formalin-Fixed Paraffin-Embedded (FFPE) Admixtures of Tumor Cells

SAN DIEGO, Feb. 11, 2016 /PRNewswire/ — Scientists from Silicon Biosystems Menarini today reported a groundbreaking cell-isolation method that opens the door to genetic analysis of previously preserved tumor sam­ples that until now have been impossible to isolate with 100 percent purity. Utilizing the com­pany’s DEPArray™ technology to isolate specific tumor types in various stages of development, the researchers were able to characterize genetic variants of these cells that are clinically relevant, and may change the way tumor biopsies are characterized and diagnosed, laying the foundation for more precise cancer treatments. The study was reported today in the journal, Scientific Reports, a Nature publication.* 

The DEPArray cell-isolation system optimizes high-throughput genetic analysis — so-called “next genera­tion sequencing” (NGS) methods of molecular characterization — by adding digital precision to the pro­cess of sample preparation. “NGS has the potential to revolutionize clinical oncology by providing direct, actionable molecular information about tumor cells. Such information can be critical to developing per­sonalized medical treatments against specific tumor types, as well as to stratify patients for appropriate clinical trials,” explained Nicolo Manaresi, Ph.D., Chief Scientific Officer at Silicon Biosystems Menarini and the lead investigator in the study.

Overcoming FFPE and Tumor Heterogeneity
The power of NGS, however, is largely negated by FFPE — the de facto laboratory practice of preserving biopsy samples in formalin and embedding them with paraffin wax so they can be thin-sectioned for microscopic viewing. NGS is further compromised by “tumor heterogeneity” — the fact that tumor cells undergo dynamic cellular changes over time, constantly generating variant cell subpopulations that spread throughout the body. Moreover, heterogeneity inside the tumor cell population itself limits the possibility to identify drivers of tumor development, as low represented clones may actually be the ones responsible for more malignant traits.

Targeted cancer treatment requires monitoring these cell changes at the molecular level, especially those cells that have acquired drug resistance. Thus primary tumors become less relevant sources of molecular information, while monitoring of the evolution of specific cells in the course of the disease is critical for tailoring more precise patient treatment.

“Pre-analytical resolution of tumor heterogeneity is a major step forward for precision medicine,” added Dr. Manaresi. “By enabling the addition of precise sample preparation to the NGS workflow, the DEPArray system brings precision medicine concepts such as personalized therapy, molecular monitor­ing of response to therapy, and liquid biopsy into the realm of practical possibility.”

Unlocking the Power of Next Generation Sequencing for Tumor Analysis
Current available technology to solve sample heterogeneity, such as laser-capture microdissection and fluorescence-activated cell sorting (FACS) lack the accuracy and purity required for clinical use, and their power is often limited by the size and quality of the starting sample materials. The studied showed that the DEPArray cell-sorting and isolation technology, followed by NGS analysis, can reveal comprehensive genomic information from any FFPE sample, regardless of sample cellularity and size of the specimen. Moreover, the methodology informs a new model for conducting clinical biopsies of tumors, as well as for performing translational cancer research and the way new cancer drugs are developed and biomarkers discovered.

“The method we have developed, based on a pre-analytic digital cell separation from FFPE samples, achieves 100% purity of the sample, substantially reverting the DNA composition to a germline-like situa­tion where NGS techniques can display all their power and reliability,” said Dr. Manaresi. “Data analysis and interpretation of results are also drastically simplified and different classes of genetic alterations can be solved with unprecedented precision.”

Selection and Isolation with Single-Cell Precision
Based on the principle of dielectrophoresis, which exploits the ability of a non-uniform electric field to move cells in a spatial gradient, the DEPArray platform provides precise image-based cell selection for identification and sorting of individual cells, or pools of cells, at 100% purity for further genetic analysis or culturing. The system enables investigators to recover desired live cells from a mixed tissue sample, such as FFPE samples, or from frozen tumor specimens, and cell cultures.

About Silicon Biosystems Menarini
Silicon Biosystems Menarini, based in San Diego, Calif. and Bologna, Italy, is a wholly owned subsidiary of The Menarini Group, a multinational pharmaceutical, biotechnology and diagnostics company head­quartered in Florence, Italy, with a heritage of over 130 years and over 16,000 employees in more than 100 countries. The company manufactures and sells the DEPArray system, which enables researchers to automatically identify, quantify, and recover individual rare cells with single-cell precision. For more information visit http://www.siliconbiosystems.com.

* Bolognesi, C. et al. Digital Sorting of Pure Cell Populations Enables Unambiguous Genetic Analysis of Heterogeneous Formalin-Fixed Paraffin-Embedded Tumors by Next Generation Sequencing. Sci. Rep. 6, 20944; doi: 10.1038/srep20944 (2016).

 

SOURCE Silicon Biosystems Menarini

Postdoctoral Fellow, Assembly of Postsynaptic Signaling Complexes – Janssen Research & Development, LLC. – San Diego, CA

February 11, 2016 – 12:34 am

Requisition ID: 2168160128 Janssen Research & Development, L.L.C., a Johnson and Johnson Company is hiring a Postdoctoral Scientist, Postdoctoral Fellow to
From Johnson & Johnson Family of Companies – 11 Feb 2016 07:34:34 GMT
– View all San Diego jobs

Research Scientist I, Cell Biologist, Human Cell Core – Vertex Pharmaceuticals – San Diego, CA

February 10, 2016 – 11:44 pm

Vertex is a global biotechnology company that aims to discover, develop and commercialize innovative medicines so people with serious diseases can lead better…
From Vertex Pharmaceuticals – 11 Feb 2016 06:44:10 GMT
– View all…

Process Development Consultant – Sartorius Corporation – San Diego, CA

February 10, 2016 – 6:26 pm

Bachelor’s degree in biology, biotechnology or engineering combined with elaborate understanding of MAB, Vaccine, ADC, Plasma, gene therapy, cell therapy…
From Sartorius Corporation – 11 Feb 2016 04:34:30 GMT
– View all San D…

QA Document Control Specialist (North County San Diego)

February 10, 2016 – 5:06 pm

POSITION: QA DOCUMENT CONTROL SPECIALIST
SUMMARY:
Under the supervision of the President/Manager of Operations, the QA Document Control Specialist is responsible for all matters related to quality under the FDA’s GMP guidelines. These responsibilit […

Purchasing & Imports Specialist (Carlsbad)

February 10, 2016 – 4:36 pm

POSITION: PURCHASING & IMPORTS SPECIALIST
SUMMARY:
Under the direct supervision of the President/Manager of Operations, the Purchasing & Imports Specialist is responsible for purchasing products and tracking the shipments from international supplie […]

Genomic Health Announces 2016 Financial Outlook and Provides 2015 Fourth Quarter and Year-End Financial Results

February 10, 2016 – 2:05 pm

Expects to Deliver Double-Digit Test and Revenue Growth in 2016Plans to Launch First Liquid Biopsy Test Mid-2016Conference Call Today at 4:30 p.m. ET

REDWOOD CITY, Calif., Feb. 10, 2016 /PRNewswire/ — Genomic Health, Inc. (Nasdaq: GHDX) today reported financial results and business progress for the quarter and year ended December 31, 2015.

Revenue was $74.5 million in the fourth quarter of 2015, compared with $69.1 million in the fourth quarter of 2014, an increase of 8 percent. On a constant currency basis, revenue increased 9 percent compared with the same period in the prior year.

U.S. revenue was $63.9 million in the fourth quarter of 2015, an increase of 9 percent compared with the same period in the prior year. International revenue was $10.6 million in the fourth quarter of 2015, compared with $10.3 million a year ago. International revenue was reduced by $0.6 million from foreign exchange rate differences due to the stronger dollar as compared to a year ago.

Revenue was $286.8 million in the full year 2015, compared with $275.7 million in 2014, an increase of 4 percent. International revenue for the full year 2015 was $41.4 million, compared with $45.0 million a year ago. For the year ended December 31, 2015, international revenue was reduced by approximately $3.0 million from foreign exchange rate differences due to the stronger dollar as compared to a year ago.

More than 107,030 Oncotype DX® test results were delivered for the year ended December 31, 2015, an increase of 12 percent, compared with more than 95,610 test results delivered in 2014. In the fourth quarter of 2015, more than 27,730 Oncotype DX test results were delivered, an increase of 12 percent, compared with more than 24,770 test results delivered in the same period in 2014. Prostate tests delivered in the United States for the full year grew 75 percent compared to the prior year and represented approximately 8 percent of total test volume in 2015. International tests delivered in the full-year grew 19 percent compared to the prior year and represented approximately 21 percent of total test volume in 2015.

“We expect the strong momentum generated across our business in 2015, combined with new compelling global prospective outcomes evidence for the Oncotype DX breast cancer test and recent Medicare coverage for the Oncotype DX prostate cancer test, to lead to double-digit test and revenue growth in 2016,” said Kim Popovits, Chairman of the Board, Chief Executive Officer and President of Genomic Health. “Additionally, we are excited to continue our impact in making cancer care smarter by launching our first liquid biopsy test, Oncotype SEQ™, in mid-2016.”

Operating loss for the fourth quarter narrowed to $3.5 million compared with $6.0 million for the fourth quarter of 2014. Net loss was $3.2 million for the fourth quarter of 2015 and includes a $0.8 million tax credit in the quarter resulting from a change in fair value of the company’s investment in a marketable security. Basic and diluted net loss per share was $0.10 for the fourth quarter of 2015 compared with basic and diluted net loss per share of $0.20 for the same period in 2014.

Additional Year-End 2015 Financial Results

Operating loss was $34.5 million for the year ended December 31, 2015, compared with an operating loss of $23.6 million for the year ended December 31, 2014. The operating loss for the year ended December 31, 2015 includes a non-recurring first quarter charge of $5.5 million in R&D associated with the wind-down of a breast cancer collaboration.

Net loss was $33.8 million for the year ended December 31, 2015, compared with a net loss of $24.6 million for the year ended December 31, 2014. Basic and diluted net loss per share was $1.04 for the year ended December 31, 2015, compared with a basic and diluted net loss per share of $0.78 for the year ended December 31, 2014.

Cash and cash equivalents and short-term investments at December 31, 2015 were $76.8 million, excluding the fair value of the company’s investment in a marketable security of $18.1 million, compared with $103.7 million at December 31, 2014. 

2016 Financial Guidance

“In 2016 we plan to deliver double-digit test and revenue growth and improve our net loss, while delivering positive EBITDA*,” said Brad Cole, Chief Operating Officer and Chief Financial Officer of Genomic Health. “We expect our net loss in the first half of the year to be within the full year loss guidance of $12 to $18 million and to move toward profitability in the second half of the year.”

The company is providing the following financial guidance for the full year ending December 31, 2016:

  • Total revenue of $320 to $335 million, representing growth of between 12 and 17 percent compared to 2015;
  • Net loss between $12 and $18 million at the mid-point of revenue guidance, excluding the effect of the company’s investment in a marketable security, or basic net loss per share of between $0.37 and $0.55; and
  • Oncotype DX tests delivered of 117,500 to 121,000, representing growth of between 10 and 13 percent compared to 2015.

*EBITDA, or earnings before interest, taxes, depreciation and amortization, is a non-GAAP term.

Recent Business Highlights:

Oncotype DX Commercial Progress

  • Implemented new enterprise-wide platform (ERP) to add novel capabilities and provide the ability to scale the company’s growing business.
  • Expanded coverage of the Oncotype DX breast cancer test for patients with 1-3 positive nodes to include 11 million additional lives through new policies with Health Net, Blue Cross Blue Shield of Florida and Independent Blue Cross. This brings the total number of node-positive covered lives to more than 161 million U.S. lives.
  • Received positive reimbursement decisions for the Oncotype DX breast cancer test in four additional regions of Spain bringing the total number of ex-U.S. lives covered to 196 million.
  • The Centers for Medicare and Medicaid Services (CMS), which administers the Medicare program, issued its final Clinical Laboratory Fee Schedule (CLFS) for 2016, which will allow the Medicare Administrative Contractor (MAC) to continue to set payment for the Oncotype DX colon cancer test through 2016, as has been done since initiation of coverage in 2011.

 Pipeline, Presentations and Publications

  • Announced plans to launch first liquid biopsy test, Oncotype SEQ™, a blood-based mutation panel that uses next-generation sequencing to identify select actionable genomic alterations for the treatment of patients with late-stage lung, breast, colon, melanoma, ovarian or gastrointestinal cancer, in mid-2016. Oncotype SEQ represents the first of several liquid biopsy tests that Genomic Health plans to deliver through the introduction of its Oncotype IQ™ Genomic Intelligence Platform.
  • Urology published a meta-analysis of the original Oncotype DX clinical validation studies demonstrating the ability of the Genomic Prostate Score (GPS) to refine risk stratification for low- and intermediate-risk patients with greater precision compared to clinical classifiers alone.
  • Positive results from a large prospective outcomes study in Germany were accepted for publication in the Journal of Clinical Oncology. Led by the Women’s Healthcare Study Group, the PlanB study demonstrated that women with breast Recurrence Score® results of 11 or less who were treated with hormonal therapy alone had excellent outcomes with 98 percent disease-free survival rates at three years despite having intermediate- or high-risk disease by traditional parameters.
  • Received acceptance to present five year outcomes data from the PlanB study in an oral presentation at the upcoming European Breast Cancer Conference in March.
  • Announced results from multiple Oncotype DX breast cancer test studies at the 38th CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) reconfirming that Oncotype DX accurately predicts clinical outcomes – including risk of recurrence and breast cancer survival – in early-stage patients with invasive breast cancer. Data include results from the Surveillance, Epidemiology, and End Results (SEER) program of the National Cancer Institute (NCI); complete results from a multi-center study from Clalit Health Services, the largest health maintenance organization in Israel; additional analyses from the NCI-sponsored Trial Assigning IndividuaLized Options for Treatment (Rx), or TAILORx; and the German PlanB study.

Conference Call Details
To access the live conference call today, February 10 at 4:30 p.m. Eastern Time via phone, please dial (877) 303-7208 from the United States and Canada or +1 (224) 357-2389 internationally.  The conference ID is 34365800.  Please dial in approximately ten minutes prior to the start of the call.  To access the live and subsequently archived webcast of the conference call, go to the Investor Relations section of the company’s website at http://investor.genomichealth.com/events.cfm. Please connect to the web site at least 15 minutes prior to the call to allow for any software download that may be necessary.

About Genomic Health
Genomic Health, Inc. (NASDAQ: GHDX) is the world’s leading provider of genomic-based diagnostic tests that address both the overtreatment and optimal treatment of cancer, one of the greatest issues in healthcare today. With its Oncotype IQ™ Genomic Intelligence Platform, the company is applying its world-class scientific and commercial expertise and infrastructure to lead the translation of clinical and genomic big data into actionable results for treatment planning throughout the cancer patient journey, from diagnosis to treatment selection and monitoring. The Oncotype IQ portfolio of genomic tests and services currently consists of the company’s flagship line of Oncotype DX gene expression tests that have been used to guide treatment decisions for more than 600,000 cancer patients worldwide. Genomic Health is expanding its test portfolio to include additional liquid and tissue-based tests. The company is based in Redwood City, California, with international headquarters in Geneva, Switzerland. For more information, please visit, www.GenomicHealth.com and follow the company on Twitter: @GenomicHealthFacebookYouTube and LinkedIn.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating the company’s beliefs regarding its liquid biopsy platform and the timing of a liquid biopsy test; the company’s intent to continue its investments in DCIS, prostate cancer and international markets; the company’s full year 2015 results; the attributes and focus of the company’s product pipeline; the ability of any potential tests the company may develop to optimize cancer treatment; and the ability of the company to develop and commercialize additional tests in the future. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the risks and uncertainties associated with the regulation of the company’s tests; the results of clinical studies and their impact on reimbursement and adoption; the applicability of clinical study results to actual outcomes; the company’s ability to develop and commercialize new tests and expand into new markets domestically and internationally; the risk that the company may not obtain or maintain sufficient levels of reimbursement, domestically or abroad, for its existing tests and any future tests it may develop; the risks of competition; unanticipated costs or delays in research and development efforts; the company’s ability to obtain capital when needed and the other risks set forth in the company’s filings with the Securities and Exchange Commission, including the risks set forth in the company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2015. These forward-looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward-looking statements.

NOTE: The Genomic Health logo, Oncotype, Oncotype DX, Recurrence Score, DCIS Score, Oncotype SEQ, and Oncotype IQ are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners.

 

GENOMIC HEALTH, INC.

Condensed Consolidated Statements of Operations

(In thousands, except per share amounts)

Three Months Ended

Twelve Months Ended

December 31,

December 31,

2015

2014

2015

2014

Unaudited

Unaudited

REVENUES:

Product revenues – United States

$

63,918

$

58,794

$

245,378

$

230,657

Product revenues – Outside of the United States

10,582

10,332

41,447

45,049

Total revenues

74,500

69,126

286,825

275,706

OPERATING EXPENSES (1)(2):

Cost of product revenues

14,078

12,501

53,591

48,742

Research and development

12,605

12,549

59,798

53,076

Selling and marketing

35,593

35,144

143,557

137,846

General and administrative

15,755

14,919

64,348

59,669

Total operating expenses

78,031

75,113

321,294

299,333

Loss from operations

(3,531)

(5,987)

(34,469)

(23,627)

Interest income

58

48

221

192

Other income (expense), net

(291)

(227)

(498)

(764)

Loss before income taxes

(3,764)

(6,166)

(34,746)

(24,199)

Income tax expense (benefit)

(587)

101

(996)

393

Net loss

$

(3,177)

$

(6,267)

$

(33,750)

$

(24,592)

Basic and diluted net loss per share

$

(0.10)

$

(0.20)

$

(1.04)

$

(0.78)

Shares used in computing basic and diluted net loss per share

32,645

31,791

32,382

31,453

(1)

Included in operating expenses for the three months ended December 31, 2015 were non-cash charges of $6.0 million, including $4.0 million of stock-based compensation expense and $2.0 million of depreciation and amortization expenses, compared with non-cash charges for the same period in 2014 of $5.6 million, including $3.9 million of stock-based compensation expense and $1.7 million of depreciation and amortization expenses.

(2)

Included in operating expenses for the twelve months ended December 31, 2015 were non-cash charges of $23.1 million, including $16.0 million of stock-based compensation expense and $7.1 million of depreciation and amortization expenses, compared with non-cash charges for the same period in 2014 of $23.4 million, including $16.5 million of stock-based compensation expense and $6.9 million of depreciation and amortization expenses.

 

GENOMIC HEALTH, INC.

Condensed Consolidated Balance Sheets

(In thousands)

As of
December 31,
2015

As of
December 31,
2014

(Unaudited)

(1)

Cash and cash equivalents

$

32,533

$

29,726

Short-term marketable securities (2)

62,410

73,934

Accounts receivable, net

36,531

34,916

Prepaid expenses and other current assets

10,844

9,944

Total current assets

142,318

148,520

Property and equipment, net

39,746

21,860

Other assets

1,921

15,541

Total assets

$

183,985

$

185,921

Accounts payable

$

8,395

$

6,987

Accrued expenses and other current liabilities

33,656

31,016

Deferred revenues

431

335

Other liabilities

2,410

2,070

Stockholders’ equity

139,093

145,513

Total liabilities and stockholders’ equity

$

183,985

$

185,921

(1)

The condensed consolidated balance sheet at December 31, 2014, has been derived from the audited consolidated financial statements at that date included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2014.

(2)

Included in short-term marketable securities as of December 31, 2015, was $18.1 million of corporate equity securities, representing the Company’s investment in Invitae Corporation.

 

Logo – http://photos.prnewswire.com/prnh/20130425/SF01493LOGO

 

SOURCE Genomic Health, Inc.